Alnylam Pharmaceuticals, Inc. announced today that it has granted Bio-Rad a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi ... more
First Demonstration of Therapeutic Gene Silencing in Primates with Systemic RNAi
Alnylam Pharmaceuticals, Inc. announced the first published demonstration in primates that a systemically delivered RNAi therapeutic can potently silence an endogenous disease-causing gene in a clinically relevant manner. Alnylam and its collaborators at Protiva Biotherapeutics, Inc., demonstrated silencing in primates of the gene for apolipoprotein B (apoB), a protein involved in cholesterol metabolism, with clinically significant efficacy as demonstrated by reductions in levels of cholesterol and low-density lipoproteins (LDL). According to Alnylam, this peer-reviewed research, published in Nature, represents a major advance because it suggests that an RNAi therapeutic can be effective when delivered systemically using a dosage appropriate for application in future human clinical studies.
In the published research, Alnylam scientists and collaborators demonstrated potent silencing in primates of the gene for apoB, a disease-causing protein which to date has not been amenable to targeting with traditional small molecule, protein, or antibody therapies. The achievement of this result by systemic administration through the bloodstream demonstrates the broad potential of RNAi therapeutics to target disease-causing genes, and significantly expands the previously demonstrated opportunity for RNAi therapeutics to treat human disease by direct administration to sites of disease, such as with respiratory or ocular delivery.
In the study Alnylam scientists and collaborators showed that systemic delivery in non-human primates of a chemically optimized small interfering RNA, or siRNA, can result in silencing of the apoB messenger RNA (mRNA), leading to significant reductions in blood levels of the apoB protein. These effects were proven to occur through an RNAi-mediated mechanism, and resulted in immediate, potent, and durable therapeutic efficacy. The siRNAs were formulated with liposomes that enable delivery to liver cells. The observed therapeutic effects included significant reductions in serum levels of cholesterol and LDL, which together represent the so-called "bad cholesterol" associated with development of atherosclerosis and coronary artery disease. Following administration of a single intravenous bolus dose at low dosages from 1.0-2.5 mg/kg, these reductions were observed as early as 24 hours after treatment and lasted for at least 11 days. A single siRNA injection resulted in dose-dependent silencing of apoB mRNA expression, with maximal silencing of over 90%. The silencing of apoB was proven to occur through an RNAi-mediated mechanism of action. In addition, plasma apoB levels were reduced by more than 75%, cholesterol levels by more than 60%, and LDL levels by more than 80%. In the study of 18 animals, the treatment was well tolerated with only transient liver enzyme elevation observed at the highest dose.
- Protiva Biotherapeutics
- liver cells
- gene silencing
- clinical trials
Novartis and Alnylam Pharmaceuticals, Inc. announced that they have formed a new collaboration to develop RNAi therapeutics for pandemic flu. This collaboration is in addition to the collaboration formed by the two companies in September 2005, and significantly reinforces the development pr ... more
- 1Detect neurodegenerative diseases such as Alzheimer's by a simple eye scan?
- 2Fluorescence microscopy at highest spatial and temporal resolution
- 3The Mechanics of the Immune System
- 4Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis
- 5Quick look under the skin
- 6New ion trap to create the world's most accurate mass spectrometer
- 7How does your computer smell?
- 8Clocking electron movements inside an atom
- 9Sartorius closes 2020 with strong growth
- 10A clear path to better insights into biomolecules
- Cancer screening from home?
- Predicting the probability of death
- Many researchers are familiar with the problem: Before there are any new fin ...
- DZNE’s First Spin-off “Neuron–D” Uses Innovative Technology for Drug Testing
- Corona Genome Sequencing: Start-up "nanozoo" Launches Portal for Free Data A ...